Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications

Francisco Espinoza, Sylvie Fabre, Yves Marie Pers*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

22 Citas (Scopus)


Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks, since this is a ‘window of opportunity’ for treatment to modify disease progression. A treat-to-target strategy added to an aggressive therapeutic approach increases the chance of early remission, particularly in early RA patients. We conducted an overview of current therapeutic strategies leading to remission in early RA patients. We also provide interesting predictive factors that can guide the RA management strategy with regard to disease-modifying treatment and/or drug-free remission.
Idioma originalInglés
Páginas (desde-hasta)107-118
Número de páginas12
PublicaciónTherapeutic Advances in Musculoskeletal Disease
EstadoPublicada - 1 ago. 2016

Nota bibliográfica

Publisher Copyright:
© The Author(s), 2016.

Palabras clave

  • disease-modifying antirheumatic drugs
  • early rheumatoid arthritis
  • predictive factors
  • remission
  • rheumatoid arthritis


Profundice en los temas de investigación de 'Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications'. En conjunto forman una huella única.

Citar esto